Old Second Bancorp Shares Cross Above 200-Day Moving Average
Old Second Bancorp (NASDAQ:OSBC) stock crossed above its 200-day moving average, signaling a potential bullish trend. This technical indicator suggests increased investor attention, with analysts offering mixed ratings but setting price targets as high as $23. The regional bank's stock closed at $20.76 with solid trading volume, and its last earnings report showed EPS exceeding estimates.
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors despite daily gains
Quest Diagnostics Inc. (DGX) shares rose 1.36% on Monday, closing at $198.96, marking its third consecutive day of gains. Despite this rise, the stock underperformed compared to the broader market indices, with the S&P 500 Index (SPX) increasing by 0.44% and the Dow Jones Industrial Average (DJIA) rising by 0.36%.
Medical Foods Market Is Going to Boom |• Abbott • Danone
Worldwide Market Reports has released a comprehensive research study on the Medical Foods Market, forecasting significant growth between 2026 and 2033. The report analyzes key market drivers, challenges, opportunities, and restraints, providing insights into the competitive landscape, market segmentation, and regional trends. It aims to assist stakeholders in making informed investment decisions and understanding the future trajectory of the global Medical Foods market.
5,900 Shares in Quest Diagnostics Incorporated $DGX Purchased by Capital Management Associates Inc
Capital Management Associates Inc. has acquired a new stake of 5,900 shares in Quest Diagnostics (NYSE:DGX) valued at approximately $1.024 million, making it part of an investor base that is largely institutionally owned. Quest Diagnostics recently surpassed Q4 estimates, provided strong FY2026 guidance, increased its dividend, and authorized a $1.0 billion share buyback. Analysts currently hold a "Hold" consensus rating with an average target price of $211.46, although some have raised their targets to $220–$225.
DaVita (NYSE:DVA) - Stock Analysis
This report provides a comprehensive analysis of DaVita (NYSE:DVA), a kidney dialysis service provider, highlighting its current stock performance, valuation, future growth prospects, and financial health. The company is trading below its estimated fair value, with earnings projected to grow by 5.64% annually. Key narratives discuss the impact of policy shifts, operational recovery, international expansion, and integrated kidney care on its outlook and margins.
Quest Diagnostics Incorporated (DGX) Stock forecasts
This article appears to be a stub or an error page from Yahoo Finance, intended to display stock forecasts for Quest Diagnostics Incorporated (DGX). However, it contains no actual content regarding Quest Diagnostics' stock forecasts, financial data, or analysis, and instead shows multiple "Error while retrieving data" messages. The page structure suggests it is part of a larger financial news platform.
DGX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event updates for Quest Diagnostics (DGX), including their upcoming Q1 2026 financial results announcement and the launch of an AI companion for lab data analysis. It also highlights leadership appointments, dividend increases, and stock performance milestones for the company.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, holding a critical niche in cancer genetics testing with laboratories across the U.S. While the company operates in a high-growth sector and strategically serves both clinical oncology and pharmaceutical drug development, it faces significant profitability hurdles with ongoing net losses due to heavy investments. North American investors are advised to monitor its progress toward profitability and navigate the competitive diagnostics market before making investment decisions.
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles
NeoGenomics Inc. specializes in precision oncology diagnostics, offering cancer genetics testing and pharmaceutical services, primarily in the U.S. While the company operates in a high-growth sector driven by rising cancer rates and advancing therapies, it faces profitability hurdles with persistent net losses due to heavy investments. Investors are advised to watch their growth trajectory, market share gains in precision oncology, and the path to profitability, balancing growth prospects against execution risks and competitive pressures.
Quest Diagnostics (DGX) director defers pay into 198 phantom stock units
Timothy C. Wentworth, a director at Quest Diagnostics (DGX), has deferred his cash compensation and received 198 phantom stock units. These units, which derive from the company's Deferred Compensation Plan for Directors, will be paid out in cash when his service as a director concludes. This transaction, categorized as a grant/award acquisition, is part of his compensation rather than a direct stock purchase.
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Quanterix (QTRX) has made significant advancements in Alzheimer's blood testing, including submitting a multi-analyte algorithmic blood test to the FDA and partnering to offer non-invasive biomarker tests nationally. Despite a modest adjustment to its price target reflecting slightly lower revenue and profit margin assumptions, the company's valuation remains stable at a Fair Value of $7.33. These developments, alongside new CEO appointment and promising 2026 revenue guidance, position Quanterix for strong long-term growth in the biomarker diagnostics market.
In 211 myeloma samples, OGM found abnormalities older tests missed
Bionano (Nasdaq: BNGO) announced a multicenter study published in April 2026, demonstrating that optical genome mapping (OGM) outperforms traditional cytogenetic methods in analyzing multiple myeloma (MM) samples. The study, involving 211 MM samples, found that OGM identified relevant abnormalities in 92% of cases previously deemed normal by karyotype and resolved 82% of samples that failed karyotyping, also detecting complex events like chromoanagenesis in ~29% of samples. This suggests OGM can provide a more comprehensive view of genomic alterations and addresses medical society recommendations for MM analysis, potentially driving increased adoption and utilization of OGM.
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies announced a 146% year-over-year surge in unit sales for its CyPath® Lung diagnostic in Q1 2026, exceeding internal projections. This growth reflects increasing physician adoption and clinical use of the noninvasive lung cancer diagnostic, addressing a large and expanding market for pulmonary nodule management and lung cancer survivor surveillance. The company is advancing further initiatives, including a large-scale clinical study and R&D pipeline for other diagnostic tests, while focusing on commercial strategy execution.
Small cap wrap: Alvopetro Energy, NanoViricides, New Era Energy & Digital, Digi Power X…
This article provides a small cap wrap-up featuring multiple companies and their recent developments. Key highlights include Alvopetro Energy securing increased natural gas sales, NanoViricides expecting to start a Phase II clinical trial for mpox, and New Era Energy & Digital signing a non-binding letter of intent for a joint venture to develop data centers. Additionally, it covers financial growth for Bit Digital Inc. and Digi Power X Inc., and clinical advancements for Recce Pharmaceuticals, Tiziana Life Sciences, and Medicus Pharma.
Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote
Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The proxy statement details executive compensation for 2025, outstanding equity awards, and director compensation.
Competitive Analysis: Key Market Leaders and New Entrants in the Lyme Disease Testing Industry
The Lyme disease testing market is projected to reach $16.46 billion by 2030, growing at a CAGR of 9.0%, driven by advancements in diagnostics and increased awareness of tick-borne illnesses. Key trends include AI-assisted tools, home-testing kits, and multi-disease panels. Companies like Roche, Thermo Fisher Scientific, and Quest Diagnostics are leading innovation, with strategic partnerships and technological advancements enhancing early and precise detection methods.
Infectious Disease Diagnostics Testing Market Overview, Key Trends, and Major Player Analysis
The infectious disease diagnostics testing market is projected to reach $65.49 billion by 2030, growing at a CAGR of 9.0%. This growth is driven by increasing global health challenges, demand for rapid diagnostic tools, and investments in healthcare. Key trends include stronger demand for early detection, wider adoption of point-of-care testing, and increased use of molecular diagnostics.
Should Labcorp’s Expanded Illumina Oncology Partnership Reshape the Precision Medicine Story for LH Investors?
Labcorp and Illumina have expanded their precision oncology partnership to enhance access to next-generation sequencing-based cancer tests, including co-commercializing both tissue and liquid biopsy options. This collaboration aims to support drugmakers and strengthen payer coverage for comprehensive genomic profiling. While the partnership reinforces Labcorp's oncology testing franchise, investors are cautioned that it may not significantly alter short-term financial sensitivities to reimbursement shifts or broader economic headwinds.
Whoop Raises $575M at $10.1B Valuation, Abbott Joins as Investor
Whoop, the human performance company known for its screenless wearable, has raised $575 million in a Series G round, achieving a $10.1 billion valuation. Healthcare giant Abbott has joined as a strategic investor, signaling Whoop's expansion into personalized, preventive health. The capital will support U.S. growth and international expansion, further building on its 2.5 million global members.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
This article identifies Quest Diagnostics (DGX) as a strong value stock. It likely details why the company presents a good investment opportunity based on value metrics, encouraging readers to access a free report for further recommendations.
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands
NeoGenomics Inc (NASDAQ: NEO) plays a crucial role in the cancer diagnostics sector by providing specialized oncology testing services essential for precision medicine. The company focuses on innovation in next-generation sequencing and companion diagnostics, positioning itself competitively against larger labs through specialization and proprietary assays. Investors can find long-term growth potential in NeoGenomics due to its alignment with rising cancer incidence rates and its service-oriented model delivering steady cash flows in the robust healthcare growth sector.
What Is a DUTCH Test? The Hormone Panel Explained
Many women experience frustration when seeking comprehensive hormone testing from their doctors, particularly when dealing with perimenopausal symptoms. The DUTCH (Dried Urine Test for Comprehensive Hormones) test is presented as a more thorough alternative to standard blood tests, analyzing hormone production, usage, and elimination over time. However, this detailed test often comes with a significant out-of-pocket cost as it is typically not covered by insurance or readily ordered by conventional medical practitioners.
Emerging Sub-Segments Transforming the Drug Screening Market Landscape
The drug screening market is projected to reach $19.2 billion by 2030, growing at a CAGR of 14.5%, driven by technological advancements, regulatory demands, and innovations like AI-powered analytics and portable devices. Key growth areas include rapid testing kits, automated laboratory systems, digital reporting, and point-of-care testing. Strategic acquisitions and collaborations, such as Premier Biotech's acquisition of Desert Tox and Neopharma Technologies' partnership with Impairment Science, are further shaping the industry by expanding testing capacities and integrating advanced assessment tools.
A Look At Quest Diagnostics (DGX) Valuation After Recent Share Price Swings
Quest Diagnostics (DGX) has experienced recent stock volatility, dropping 8% over the past month, but maintaining positive returns over three months and a year. The company's current stock price of $195.51 is considered undervalued compared to a fair value estimate of $218.50, driven by analyst expectations of future earnings growth and profit margins. Investors are encouraged to consider the potential upsides while also being aware of risks like reimbursement cuts and rising operational costs.
Labcorp EVP Meltzer sells $224k in shares
Labcorp Executive Vice President, Operations, Jonathan C. Meltzer, sold 839 shares of company stock for $224,054 on March 27, 2026. Prior to this, on March 26, 2026, Meltzer acquired 2,388 shares through a performance award and had 711 shares withheld for tax obligations. Following these transactions, Meltzer directly owns 3,620.3256 shares of Labcorp Holdings Inc., with the stock showing a 16% return over the past year and analysts projecting a 12% upside.
Beat the Market the Zacks Way: Equinix, Archrock, Cheniere Energy in Focus
This article highlights how Zacks Investment Research's methodologies, including Zacks Rank, Zacks Recommendation, Focus List, ECAP, and ECDP, have successfully guided investors through recent market volatility. It cites specific stock examples like Equinix, Archrock, and Cheniere Energy that have seen significant gains after being recommended by Zacks, outperforming the S&P 500. The article also touches upon current market conditions characterized by uncertainty, rising oil prices, and concerns about stagflation.
Abbott integrates cancer tests into Flatiron’s EMR platform
Abbott and Flatiron Health have announced the integration of Abbott's Precision Oncology test portfolio into Flatiron's OncoEMR platform, streamlining access for cancer care providers. This integration allows healthcare professionals to digitally order Abbott's cancer tests and receive results directly within their existing clinical workflow. Despite Abbott shares trading near a 52-week low, this collaboration aims to reduce administrative burdens and enhance the accessibility of crucial cancer diagnostic tools across Flatiron's network.
Assenagon Asset Management S.A. Buys 19,361 Shares of Quest Diagnostics Incorporated $DGX
Assenagon Asset Management S.A. significantly increased its stake in Quest Diagnostics (NYSE:DGX) by 346.5% in the fourth quarter, purchasing an additional 19,361 shares, bringing its total holdings to 24,949 shares valued at $4.33 million. This increase in institutional ownership, with currently 88.06% of the stock held by institutional investors, follows Quest Diagnostics beating its Q4 earnings and revenue estimates. The company also announced a $1.00 billion share repurchase program and raised its quarterly dividend, signaling confidence in its financial health.
OPKO Health Inc Stock: Business Model, Growth Drivers, and Key Investor Considerations in Diagnostics and Pharmaceuticals
OPKO Health Inc. (OPK) operates in biotechnology with dual segments: diagnostics through BioReference Health and pharmaceuticals. The company's strategy focuses on innovative testing solutions and therapeutic developments, leveraging acquisitions and strategic partnerships. Key investor considerations include the stability of its diagnostics business, the potential upside from its pharmaceutical pipeline targeting endocrine and renal disorders, and strong institutional backing, balanced against competitive and regulatory risks.
U.S. Hyaluronic Acid Based Dermal Fillers Market Size [2030]
The U.S. hyaluronic acid based dermal fillers market, valued at USD 1.53 billion in 2022, is projected to grow at a CAGR of 8.2% during the forecast period due to increasing awareness of cosmetic procedures and growing per capita income. Key factors driving market growth include the rising demand for minimally invasive cosmetic procedures among young people and the aging population, coupled with continuous product innovation and FDA approvals. However, the market faces restraints from the availability of alternative dermal fillers and concerns about temporary results or side effects.
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day
Quest Diagnostics Inc. (DGX) shares experienced a 1.33% decline on Friday, closing at $195.51. This dip occurred during a generally poor trading day for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average also falling. Despite the loss, the stock's performance on this day broke a five-day winning streak.
Vanguard (DGX) amends 13G, reports 0 shares after Jan 12, 2026 realignment
The Vanguard Group amended its Schedule 13G filing for Quest Diagnostics Inc. (DGX), reporting 0 shares beneficially owned and 0% of the class as of March 13, 2026. This amendment follows an internal realignment effective January 12, 2026, which allows certain Vanguard subsidiaries and business divisions to report their holdings separately, in accordance with SEC Release No. 34-39538. This is an administrative disclosure reflecting changes in reporting structure rather than a change in investment.
VCYT SEC Filings - Veracyte 10-K, 10-Q, 8-K Forms
This page provides access to Veracyte (VCYT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights the company's activities in cancer diagnostics and genomic testing and offers AI-powered summaries of these regulatory documents for investors. The article also details recent insider transactions and Q3 2025 financial results.
Labcorp Holdings Stock: Business Model, Market Position and Investor Considerations for US50540R4092
Labcorp Holdings Inc. (NYSE: LH) is a leading provider of clinical laboratory services, with its stock trading around $266 on the NYSE. The company's business model is divided into Diagnostics and Biopharma Services, benefiting from a vast network and strategic acquisitions in genomics and at-home testing. Labcorp's strong market position, solid financial health, and strategic growth initiatives position it as a defensive play for North American investors seeking exposure to the resilient healthcare sector, despite risks like reimbursement pressures and competition.
Quest Diagnostics Earnings Preview: What to Expect
Quest Diagnostics (DGX) is set to release its Q1 2026 earnings on April 21, with analysts expecting a 6.3% rise in EPS to $2.35. The company has a history of exceeding EPS estimates and its stock has significantly outperformed the S&P 500 over the past year. Analysts rate DGX a "Moderate Buy" with an average price target indicating a 10.3% upside.
A Look At Labcorp Holdings (LH) Valuation After Illumina Alliance Puts Precision Oncology In Focus
Labcorp Holdings (LH) is under scrutiny following an expanded collaboration with Illumina, focusing on precision oncology. The article explores Labcorp's valuation, noting it's considered 12.8% undervalued with a fair value of $307.71, despite its P/E ratio of 25.2x being above the US Healthcare industry average. It advises investors to consider both the growth potential from innovative diagnostics and operational efficiencies, as well as risks from regulatory changes and Medicare pricing.
Lucid Diagnostics Reports 2025 Financial Results, Expands EsoGuard Access with VA Contract and Positive Real-World Data
Lucid Diagnostics reported its Q4 and full-year 2025 financial results, showing increased revenue but also larger net losses. A significant win for the company is a new contract with the U.S. Department of Veterans Affairs, which is expected to expand access to its EsoGuard test to millions of veterans. Additionally, positive real-world data reinforces the effectiveness and ease of use of its EsoGuard and EsoCheck products.
Quest Diagnostics Incorporated $DGX Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC significantly increased its stake in Quest Diagnostics (DGX) by 694.2% in Q4 2025, now owning 179,653 shares valued at approximately $31.18 million. Quest Diagnostics exceeded Q4 earnings expectations, reporting $2.42 EPS on $2.81 billion revenue, and raised its quarterly dividend to $0.86 while authorizing a $1.0 billion share buyback program. Analyst price targets have also been raised, contributing to a "Moderate Buy" consensus rating for the company.
Pensionfund Sabic Takes $1.11 Million Position in Quest Diagnostics Incorporated $DGX
Pensionfund Sabic initiated a new position in Quest Diagnostics (NYSE:DGX) in Q4, acquiring 6,400 shares valued at approximately $1.11 million. This move comes as Quest Diagnostics exceeded Q4 earnings expectations, announced a $1.0 billion share repurchase program, and raised its quarterly dividend. Analysts currently rate the stock with a consensus "Moderate Buy" and an average price target of $210.29.
Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation push
Exagen Inc. (ISIN: US30063K1051), a leader in autoimmune disease diagnostics, is gaining investor attention ahead of the Maryland MedTech Summit 2026. The summit, focusing on device innovations and strategies, aligns with Exagen's mission to integrate molecular diagnostics into clinical workflows, particularly with its flagship AVISE Lupus test. Investors are eyeing the company for its potential partnerships and federal initiatives that could emerge from the event, boosting its visibility and growth in the high-growth diagnostics subsector.
Exagen Inc stock gains spotlight ahead of Maryland MedTech Summit 2026 amid diagnostic innovation push
Exagen Inc. stock is drawing investor attention ahead of the Maryland MedTech Summit 2026, which focuses on medical device innovations and federal initiatives. The company, specializing in precision diagnostics for autoimmune diseases like lupus, is well-positioned to benefit from discussions on regional growth opportunities and market entry strategies within the medtech sector. Investors are particularly interested in potential partnerships and the increasing demand for advanced diagnostic solutions in rheumatology.
Cancer drug researchers gain combined patient and genomics data
Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug development, particularly for solid tumors like lung, breast, and colorectal cancers, and aid in the discovery of new biomarker-based therapies.
Moderna stands as the best performing large-cap healthcare stock YTD (XLV:NYSEARCA)
Moderna (MRNA) is highlighted as the top-performing large-cap healthcare stock year-to-date in 2026. This article presents a list of the top 10 large-cap healthcare stocks with market capitalizations over $10 billion, ranked by their year-to-date performance, noting the sector's modest gains and defensive appeal.
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Rating of "Moderate Buy" by Brokerages
Quest Diagnostics (NYSE:DGX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $210.29. The company recently surpassed quarterly earnings estimates, provided FY2026 guidance, raised its dividend, and authorized a $1.0 billion share buyback. Despite some insider selling, institutional ownership remains high, with major firms increasing their stakes.
Executive pay, board elections lead Halozyme (NASDAQ: HALO) 2026 proxy
Halozyme Therapeutics, Inc. has issued its 2026 definitive proxy statement for an online-only annual stockholder meeting on May 5, 2026. Stockholders are asked to vote on the election of two Class I directors, an advisory say-on-pay resolution for named executive officers, and the ratification of Ernst & Young LLP as auditor. The proxy details performance-based executive compensation, emphasizing strong financial results in 2025 including record revenue and significant stock price growth, and includes information on a one-time performance-based equity award for the CEO.
Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia
Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the industry.
Union Bancaire Privee UBP SA Acquires 8,744 Shares in Quest Diagnostics
Union Bancaire Privee UBP SA has acquired 8,744 shares of Quest Diagnostics Incorporated (NYSE:DGX) during the fourth quarter, a new position valued at approximately $1,517,000. This investment reflects the Swiss private bank's confidence in Quest Diagnostics' growth potential and market position as a leading provider of diagnostic information services. The transaction highlights continued institutional investor interest in the medical diagnostics industry.
8,744 Shares in Quest Diagnostics Incorporated $DGX Acquired by Union Bancaire Privee UBP SA
Union Bancaire Privee UBP SA acquired 8,744 shares of Quest Diagnostics Inc. (NYSE:DGX) in the fourth quarter, a new position valued at approximately $1.52 million. This comes as Quest Diagnostics exceeded Q4 earnings expectations with EPS of $2.42 and revenue of $2.81 billion, and announced a $1 billion share repurchase program and an increased quarterly dividend. Other institutional investors have also adjusted their holdings in the company.
How Investors May Respond To Quest Diagnostics (DGX) Expanding Blood-Based Cancer Screening And Boardroom Expertise
Quest Diagnostics (DGX) has recently expanded its role in cancer detection by partnering with Guardant Health and Helio Genomics to distribute blood-based cancer screening tests and appointed Timothy Wentworth to its board, adding healthcare expertise. These moves enhance Quest's investment narrative by solidifying its position in innovative cancer diagnostics and potentially increasing test volumes. However, the company still faces challenges from reimbursement pressures and cost inflation, which could impact its near-term financial performance and investor sentiment.
Form 144 QUEST DIAGNOSTICS INC For: 3 March By Investing.com
This article announces the filing of Form 144 for Quest Diagnostics Inc. on March 3rd. Form 144 is filed with the SEC by an insider who intends to sell restricted or control securities. The article does not provide specific details about the transaction but indicates it occurred on March 3rd.
